Overview

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-01-01

Target enrollment:

Participant gender:

Summary

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Olema Pharmaceuticals, Inc.

Collaborator:

Novartis Pharmaceuticals

Treatments:

Letrozole
ribociclib